ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.

Auteurs : Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart-Gebhart M, Rugo H, Sledge G, Thomssen C
Année : 2014
Journal : Ann Oncol
Volume : 25(10)
Pages : 1871-88

Words matter: distinguishing personalized medicine" and "biologically personalized therapeutics"."

Auteurs : Cherny NI, de Vries EG, Emanuel L, Fallowfield L, Francis PA, Gabizon A, Piccart-Gebhart M, Sidransky D, Soussan-Gutman L, Tziraki C
Année : 2014
Journal : J. Natl. Cancer Inst.
Volume : 106(12)

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO).

Auteurs : Popescu RA, Schäfer R, Califano R, Eckert R, Coleman R, Douillard JY, Cervantes A, Casali PG, Sessa C, van Cutsem E, De Vries E, Pavlidis N, Fumasoli K, Wörmann B, Samonigg H, Cascinu S, Cruz Hernández JJ, Howard AJ, Ciardiello F, Stahel RA, Piccart-Gebhart M
Année : 2014
Journal : Ann Oncol
Volume : 25(1)
Pages : 9-15

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.

Auteurs : Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart-Gebhart M, Hortobagyi G, Baselga J, Perez A, Geberth M, Csoszi T, Chouinard E, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hashimy M, Taran T, Burris HA
Année : 2014
Journal : Ann Oncol
Volume : 25(4)
Pages : 808-15

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.

Auteurs : Bonnefoi H, Litière S, Piccart-Gebhart M, Macgrogan G, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Moldovan C, Bodmer A, Zaman K, Cufer T, Campone M, Luporsi E, Malmström P, Werutsky G, Bogaerts J, Bergh J, Cameron DA
Année : 2014
Journal : Ann Oncol
Volume : 25(6)
Pages : 1128-36

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Auteurs : Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart-Gebhart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE, Pazdur R, Ditsch N, Rastogi P, Eiermann W, Von Minckwitz G
Année : 2014
Journal : Lancet
Volume : 384(9938)
Pages : 164-72

Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO).

Auteurs : Ciardiello F, Arnold D, Casali PG, Cervantes A, Douillard JY, Eggermont A, Eniu A, McGregor K, Peters S, Piccart-Gebhart M, Popescu R, van Cutsem E, Zielinski C, Stahel R
Année : 2014
Journal : Ann Oncol
Volume : 25(9)
Pages : 1673-8

Maastricht delphi consensus on event definitions for classification of recurrence in breast cancer research.

Auteurs : Moossdorff M, van Roozendaal LM, Strobbe LJ, Aebi S, Cameron DA, Dixon JM, Giuliano AE, Haffty BG, Hickey BE, Hudis CA, Klimberg VS, Koczwara B, Kühn T, Lippman ME, Lucci A, Piccart-Gebhart M, Smith BD, Tjan-Heijnen VC, van de Velde CJ, Van Zee KJ, Vermorken JB, Viale G, Voogd AC, Wapnir IL, White JR, Smidt ML
Année : 2014
Journal : J. Natl. Cancer Inst.
Volume : 106(12)

Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.

Auteurs : Fumagalli D, Blanchet-Cohen A, Brown D, Desmedt C, Gacquer D, Michiels S, Rothé F, Majjaj S, Salgado R, Larsimont D, Ignatiadis M, Maetens M, Piccart-Gebhart M, Detours V, Sotiriou C, Haibe-Kains B
Année : 2014
Journal : BMC Genomics
Volume : 15(1)
Pages : 1008

Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?

Auteurs : Sonnenblick A, Fumagalli D, Sotiriou C, Piccart-Gebhart M
Année : 2014
Journal : Cancer Treat Rev
Volume : 40(9)
Pages : 1089-95

New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors.

Auteurs : Sonnenblick A, Fumagalli D, Azim HA, Sotiriou C, Piccart-Gebhart M
Année : 2014
Journal : Clin Cancer Res
Volume : 20(24)
Pages : 6242-6

The AURORA initiative for metastatic breast cancer.

Auteurs : Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, Salgado R, Aftimos P, Saini KS, Sotiriou C, Campbell P, Dinh P, Von Minckwitz G, Gelber Rd, Dowsett M, Di Leo A, Cameron D, Baselga J, Gnant M, Goldhirsch A, Norton L, Piccart-Gebhart M
Année : 2014
Journal : Br J Cancer
Volume : 111(10)
Pages : 1881-7

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†

Auteurs : Piccart-Gebhart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J
Année : 2014
Journal : Ann Oncol
Volume : 25(12)
Pages : 2357-62

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

Auteurs : de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber Rd, Eidtmann H, Baselga J
Année : 2014
Journal : Lancet Oncol
Volume : 15(10)
Pages : 1137-46

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.

Auteurs : Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe JP, Larsimont D, Awada A, Piccart-Gebhart M, Sotiriou C, Ignatiadis M
Année : 2014
Journal : Ann Oncol
Volume : 25(10)
Pages : 1959-65

Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives.

Auteurs : Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C, Piccart-Gebhart M
Année : 2014
Journal : J. Clin. Oncol.
Volume : 32(25)
Pages : 2794-803

Biology of breast cancer during pregnancy using genomic profiling.

Auteurs : Azim HA, Brohée S, Peccatori FA, Desmedt C, Loi S, Lambrechts D, Dell orto P, Majjaj S, Jose V, Rotmensz N, Ignatiadis M, Pruneri G, Piccart-Gebhart M, Viale G, Sotiriou C
Année : 2014
Journal : Endocr Relat Cancer
Volume : 21
Pages : 545-54

Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25.

Auteurs : Pinto AC, Ferreira-Santos F, Dal Lago L, de Azambuja E, Pimentel FL, Piccart-Gebhart M, Razavi D
Année : 2014
Journal : Ecancermedicalscience
Volume : 8(null)
Pages : 425

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01).

Auteurs : de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-Jones B, Dowsett M, Gelber Rd, Piccart-Gebhart M, Suter TM
Année : 2014
Journal : J. Clin. Oncol.
Volume : 32(20)
Pages : 2159-65

Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN study.

Auteurs : Deleporte A, Paesmans M, Garcia C, Vandeputte C, Lemort M, Engelholm JL, Hoerner F, Aftimos P, Awada A, Charette N, Machiels G, Piccart-Gebhart M, Flamen P, Hendlisz A
Année : 2014
Journal : BMC Cancer
Volume : 14(1)
Pages : 385